Effect of Pyridorin in Patients With Diabetic Nephropathy

Phase 2

Completed

• Conditions: Diabetic Nephropathy

• Registration Number: NCT00320021
• Lead Sponsor: BioStratum

Brief Summary

The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-07
• Study Completion: 2003-09
• Status Verified: 2006-04
• Study First Submitted: 2006-04-27
• Study First Submitted QC: 2006-04-27
• Study First Posted: 2006-04-27
• Last Update Submitted: 2006-04-27
• Last Update Posted: 2006-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with type 1 or type 2 diabetes

• Sitting blood pressure of <=170/100 mm Hg at weeks -2 and -1

• Hemoglobin A1C <=12% at week -2

• Patients with diagnosis of diabetic nephropathy as defined by

  1. Serum Creatinine <=2.0 mg/dL at weeks -2 and -1 (PYR-205) Serum Creatinine >2.0 mg/dL but <=3.5 mg/dL at weeks -2 and -1 (PYR-207)
  2. Urinary albumin excretion >=300 mg/24 hours at week -2
  3. No other known or suspected etiology for nephropathy

• Voluntary written consent to participate in this study

Exclusion Criteria

• History of allergic or adverse response to any B vitamin
• History of major cardiovascular or cerebrovascular events
• History of cancer except adequately treated basal or squamous cell carcinoma of the skin
• History of diabetic ketoacidosis
• Autoimmune diseases
• History of significant peripheral neuropathy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in Serum Creatinine from baseline to week 26